AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 62 min read$NTRA

Chapman Steven Leonard sold $367K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,630 shares of Natera, Inc. (NTRA) at $224.99 ($0.37M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 designation generally lowers the probability of a fundamental interpretation.

02

Market read

Routine insider selling disclosure; likely sentiment-neutral with limited trading edge unless paired with other catalysts.

03

What to watch

The sale size is relatively small versus typical institutional float; without additional context (e.g., multiple concurrent insider trades), the standalone signal is limited.

Relevance 6/10Novelty 4/10Timing: Filed after-hours/next-day SEC disclosure (June 5 filing; sale dated June 4).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by Natera’s CEO/President under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CEO and President Chapman Steven Leonard sold $366,736 of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, providing limited incremental information about near-term business prospects.

Market effects

Sector

Minimal; single-company insider sale under 10b5-1 typically does not reset sector expectations.

Regional

None expected beyond NTRA-specific sentiment.

Global

None expected.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can still coincide with periods of reduced conviction or liquidity needs, potentially capping rallies.

Key entities

  • public_company
    Natera, Inc.

    Issuer of the Form 4; CEO/President sold shares under a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and President who executed the reported open-market sale.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min